EFM
E Fund Management Portfolio holdings
AUM
$2.1B
This Quarter Return
+14.76%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$2.1B
AUM Growth
+$2.1B
(+0.21%)
Cap. Flow
-$186M
Cap. Flow
% of AUM
-8.85%
Top 10 Holdings %
Top 10 Hldgs %
51.83%
Holding
429
New
31
Increased
85
Reduced
265
Closed
35
Top Buys
| 1 |
abrdn Physical Gold Shares ETF
SGOL
|
$20M |
| 2 |
iShares Gold Trust
IAU
|
$19.8M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
$19.6M |
| 4 |
SPDR Gold Trust
GLD
|
$19.6M |
| 5 |
Invesco DB Oil Fund
DBO
|
$11M |
Top Sells
| 1 |
KE Holdings
BEKE
|
$70.4M |
| 2 |
Futu Holdings
FUTU
|
$37.4M |
| 3 |
Apple
AAPL
|
$18.8M |
| 4 |
Microsoft
MSFT
|
$13.6M |
| 5 |
Applied Materials
AMAT
|
$11.3M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Consumer Discretionary | 23.94% |
| 3 | Communication Services | 11.36% |
| 4 | Healthcare | 5.11% |
| 5 | Financials | 3.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Thermo Fisher Scientific
TMO
$182B
| $647K | 0.03% |
1,596
-3,994
| -71% | -$1.62M |
|
202
Ionis Pharmaceuticals
IONS
$9.68B
| $638K | 0.03% |
16,160
-311
| -2% | -$12.3K |
|
203
Revolution Medicines
RVMD
$7.43B
| $628K | 0.03% |
17,075
+1,802
| +12% | +$66.3K |
|
204
Cytokinetics
CYTK
$5.86B
| $625K | 0.03% |
18,919
+5,136
| +37% | +$170K |
|
205
Coherent
COHR
$13.8B
| $624K | 0.03% |
+7,000
| New | +$624K |
|
206
CRISPR Therapeutics
CRSP
$4.82B
| $621K | 0.03% |
12,764
-884
| -6% | -$43K |
|
207
Stryker
SYK
$147B
| $620K | 0.03% |
1,566
-126
| -7% | -$49.8K |
|
208
Pfizer
PFE
$141B
| $614K | 0.03% |
25,337
-695
| -3% | -$16.8K |
|
209
Vaxcyte
PCVX
$4.11B
| $598K | 0.03% |
18,398
+6,079
| +49% | +$198K |
|
|
SWTX
210
DELISTED
SpringWorks Therapeutics
SWTX
| $596K | 0.03% |
12,693
+2,326
| +22% | +$109K |
|
211
Gartner
IT
$18.7B
| $591K | 0.03% |
1,463
-132
| -8% | -$53.4K |
|
212
Seagate
STX
$37B
| $590K | 0.03% |
4,088
-200
| -5% | -$28.9K |
|
213
Ralph Lauren
RL
$18.9B
| $588K | 0.03% |
2,143
| – | – |
|
214
Danaher
DHR
$144B
| $571K | 0.03% |
2,893
-411
| -12% | -$81.2K |
|
215
Akero Therapeutics
AKRO
$3.61B
| $555K | 0.03% |
10,395
+3,471
| +50% | +$185K |
|
216
Medtronic
MDT
$117B
| $546K | 0.03% |
6,258
-260
| -4% | -$22.7K |
|
217
Toll Brothers
TOL
$13.6B
| $543K | 0.03% |
4,758
| – | – |
|
218
ADMA Biologics
ADMA
$4.05B
| $541K | 0.03% |
29,683
+8,811
| +42% | +$160K |
|
219
Keysight
KEYS
$28.5B
| $539K | 0.03% |
3,291
-244
| -7% | -$40K |
|
220
PTC Therapeutics
PTCT
$4.37B
| $532K | 0.03% |
10,898
+5,564
| +104% | +$272K |
|
221
Krystal Biotech
KRYS
$4.38B
| $532K | 0.03% |
3,870
+1,612
| +71% | +$222K |
|
222
Vanguard S&P 500 ETF
VOO
$722B
| $531K | 0.03% |
935
-463
| -33% | -$263K |
|
223
Alkermes
ALKS
$4.98B
| $515K | 0.02% |
18,003
+3,943
| +28% | +$113K |
|
224
Hewlett Packard
HPE
$30.1B
| $508K | 0.02% |
24,831
-1,313
| -5% | -$26.9K |
|
225
Cigna
CI
$79.8B
| $504K | 0.02% |
1,524
-126
| -8% | -$41.7K |
|